Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 5
1998 7
1999 17
2000 11
2001 11
2002 8
2003 16
2004 10
2005 20
2006 18
2007 15
2008 26
2009 17
2010 19
2011 23
2012 39
2013 26
2014 21
2015 23
2016 25
2017 15
2018 21
2019 15
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

364 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy of co-administration of modified apple polysaccharide and probiotics in guar gum-Eudragit S100 based mesalamine mini tablets: A novel approach in treating ulcerative colitis.
Mohanta S, et al. Int J Biol Macromol 2019. PMID 30572047
In the present study, mesalamine (MES) and MAP mini tablets have been prepared and co-administered with probiotics to provide site specific release of drug. ...
In the present study, mesalamine (MES) and MAP mini tablets have been prepared and co-administered with probiotics to provide site sp …
Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications.
Richter JM, et al. Can J Gastroenterol Hepatol 2016. PMID 27446860 Free PMC article.
Ulcerative proctitis (UP) is typically treated initially with oral 5-aminosalicylate ("5-ASA"), mesalamine suppository, or mesalamine enema ("UP Rx"). ...We identified 548 patients: 327 received mesalamine suppository, 138 received oral 5-ASA, and 83 received mesalamine enema, as initial UP Rx. ...
Ulcerative proctitis (UP) is typically treated initially with oral 5-aminosalicylate ("5-ASA"), mesalamine suppository, or mesalam
Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study.
Yarlas A, et al. Inflamm Bowel Dis 2018 - Clinical Trial. PMID 29361097 Free PMC article.
We tested whether outcomes differed among patients in complete (clinical and endoscopic) remission, partial remission, or not in remission following treatment with multimatrix mesalamine. ...CONCLUSIONS: Patients in partial remission following multimatrix mesalamine treatment had HRQL and work-related outcomes equivalent to patients in complete remission. ...
We tested whether outcomes differed among patients in complete (clinical and endoscopic) remission, partial remission, or not in remission f …
New mesalamine polymeric conjugate for controlled release: Preparation, characterization and biodistribution study.
Cesar ALA, et al. Eur J Pharm Sci 2018. PMID 28958891
Mesalamine (5-ASA) consists of the first-line therapy for the treatment of ulcerative colitis; however, it has low bioavailability, can cause several systemic adverse events, and has low treatment adherence due to the inconvenient dosing scheme. ...
Mesalamine (5-ASA) consists of the first-line therapy for the treatment of ulcerative colitis; however, it has low bioavailability, c
Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial.
Lang A, et al. Clin Gastroenterol Hepatol 2015 - Clinical Trial. PMID 25724700
METHODS: We performed a multicenter randomized, placebo-controlled, double-blind study of 50 mesalamine-treated patients with active mild-to-moderate UC (defined by the Simple Clinical Colitis Activity Index [SCCAI]) who did not respond to an additional 2 weeks of the maximum dose of mesalamine oral and topical therapy. ...CONCLUSIONS: Addition of curcumin to mesalamine therapy was superior to the combination of placebo and mesalamine in inducing clinical and endoscopic remission in patients with mild-to-moderate active UC, producing no apparent adverse effects. ...
METHODS: We performed a multicenter randomized, placebo-controlled, double-blind study of 50 mesalamine-treated patients with active …
Determination of Mesalamine levels in Human Milk as a Function of Dose.
Datta P, et al. Breastfeed Med 2019. PMID 30431332
The transfer of mesalamine into human milk has to date been poorly described at the current dosages and newer formulations. This study was designed to determine transfer of mesalamine into human milk as a function of maternal dose and time, and dosage form. ...The calibration curve for mesalamine was linear over a concentration range of 0.32-200 ng/mL. Irrespective of maternal dose, mesalamine levels in milk were exceedingly low. ...
The transfer of mesalamine into human milk has to date been poorly described at the current dosages and newer formulations. This stud …
364 results
Jump to page
Feedback